These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7910053)

  • 41. Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice.
    Garaci E; Mastino A; Pica F; Favalli C
    Cancer Immunol Immunother; 1990; 32(3):154-60. PubMed ID: 2126987
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Granulocyte-macrophage colony-stimulating factor and zidovudine in the treatment of neutropenia and human immunodeficiency virus infection.
    Hewitt RG; Morse GD
    Pharmacotherapy; 1992; 12(6):455-61. PubMed ID: 1492010
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy.
    Chadwick D; Pido-Lopez J; Pires A; Imami N; Gotch F; Villacian JS; Ravindran S; Paton NI
    Clin Exp Immunol; 2003 Dec; 134(3):477-81. PubMed ID: 14632754
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine.
    Choi S; Lagakos SW; Schooley RT; Volberding PA
    Ann Intern Med; 1993 May; 118(9):674-80. PubMed ID: 8096373
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In-vitro resistance to zidovudine and alpha-interferon in HIV-1 isolates from patients: correlations with treatment duration and response.
    Edlin BR; St Clair MH; Pitha PM; Whaling SM; King DM; Bitran JD; Weinstein RA
    Ann Intern Med; 1992 Sep; 117(6):457-60. PubMed ID: 1503348
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
    Eron JJ; Benoit SL; Jemsek J; MacArthur RD; Santana J; Quinn JB; Kuritzkes DR; Fallon MA; Rubin M
    N Engl J Med; 1995 Dec; 333(25):1662-9. PubMed ID: 7477218
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group.
    Mannucci PM; Gringeri A; Savidge G; Gatenby P; Laurian Y; Pabinger-Fasching I; Martinez-Vazquez JM; Hessey EW; Steel HM
    Br J Haematol; 1994 Jan; 86(1):174-9. PubMed ID: 7912097
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
    Zylberberg H; Benhamou Y; Lagneaux JL; Landau A; Chaix ML; Fontaine H; Bochet M; Poynard T; Katlama C; Pialoux G; Bréchot C; Pol S
    Gut; 2000 Nov; 47(5):694-7. PubMed ID: 11034587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.
    Andreone P; Cursaro C; Gramenzi A; Zavagliz C; Rezakovic I; Altomare E; Severini R; Franzone JS; Albano O; Ideo G; Bernardi M; Gasbarrini G
    Hepatology; 1996 Oct; 24(4):774-7. PubMed ID: 8855175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068.
    Mildvan D; Bassiakos Y; Zucker ML; Hyslop N; Krown SE; Sacks HS; Zachary J; Paredes J; Fessel WJ; Rhame F; Kramer F; Fischl MA; Poiesz B; Wood K; Ruprecht RM; Kim J; Grossberg SE; Kasdan P; Bergé P; Marshak A; Pettinelli C
    Antivir Ther; 1996 Apr; 1(2):77-88. PubMed ID: 11321183
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low-dose oral recombinant interferon-alpha A in patients with HIV-1 infection: a blinded pilot study.
    Sperber SJ; Gocke DJ; Haberzettl CA; Pestka S
    AIDS; 1993 May; 7(5):693-7. PubMed ID: 8100421
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.
    Rasi G; DiVirgilio D; Mutchnick MG; Colella F; Sinibaldi-Vallebona P; Pierimarchi P; Valli B; Garaci E
    Gut; 1996 Nov; 39(5):679-83. PubMed ID: 9026482
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. A phase II randomized, placebo-controlled trial.
    Lane HC; Falloon J; Walker RE; Deyton L; Kovacs JA; Masur H; Banks S; Kirk LE; Baseler MW; Salzman NP
    Ann Intern Med; 1989 Jul; 111(1):41-50. PubMed ID: 2735626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thymalfasin for the treatment of chronic hepatitis C infection.
    Rustgi VK
    Ann N Y Acad Sci; 2007 Sep; 1112():357-67. PubMed ID: 17600289
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection.
    Schnittman SM; Vogel S; Baseler M; Lane HC; Davey RT
    J Infect Dis; 1994 May; 169(5):981-9. PubMed ID: 7909550
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin.
    Koup RA; Brewster F; Grob P; Sullivan JL
    AIDS; 1993 Sep; 7(9):1181-4. PubMed ID: 7692883
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells.
    Garaci E; Pica F; Mastino A; Palamara AT; Belardelli F; Favalli C
    J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):7-17. PubMed ID: 8435433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
    Frissen PH; Weverling GJ; Endert E; Jansen J; Sauerwein HP; Lange JM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):482-8. PubMed ID: 8757425
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low-dose interferon alpha combined with zidovudine in patients with AIDS-associated Kaposi's sarcoma.
    Podzamczer D; Bolao F; Clotet B; García P; Casanova A; Pagerols X; Gudiol F
    J Intern Med; 1993 Mar; 233(3):247-53. PubMed ID: 8095516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.